NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), Hema Sundar(National Comprehensive Cancer Network), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Jasmine Zain(City of Hope), Ahmad Halwani(University of Utah), Stefan K. Barta(University of Pennsylvania), Aaron C. Shaver(Vanderbilt University), Ryan A. Wilcox(University of Michigan), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Jeffrey A. Barnes(Harvard University), Sima Rozati(Johns Hopkins University), Carlos A. Torres‐Cabala(The University of Texas MD Anderson Cancer Center), Lubomir Sokol(Moffitt Cancer Center), Saurabh Rajguru(UW Health University Hospital), Weiyun Z. Ai(City College of San Francisco), Pallawi Torka(Roswell Park Comprehensive Cancer Center), Gaurav Goyal(Glocal University), Andrei R. Shustov(Seattle Cancer Care Alliance), Stephen M. Ansell(Mayo Clinic), Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Basem M. William(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Elise A. Olsen(Durham Technical Community College), Richard T. Hoppe(Stanford Medicine), Joan Guitart(Northwestern Memorial Hospital), Eric D. Jacobsen(Dana-Farber Cancer Institute), Jonathan Said(University of California, Los Angeles), Mark W. Clemens(The University of Texas MD Anderson Cancer Center), Aaron M. Goodman(University of California San Diego), Allison Jones(University of Tennessee Health Science Center), Youn H. Kim(Stanford University), Bradley M. Haverkos(University of Colorado Denver), Mary A. Dwyer(National Comprehensive Cancer Network), Barbara Pro(The University of Texas MD Anderson Cancer Center)
Cited by 62
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k